NCT Number: NCT02233907
Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
Study to obtain further information on the tolerability and efficacy of Ventilat® metered dose inhaler in long-term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year and older
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients of both genders older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
- Only patients who have not been treated with Ventilat® within the last year are to be considered for inclusion
Exclusion criteria
- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Ventilat® metered dose inhaler
Treatment and study plan
Primary outcomes
-
Change in the clinical picture
Time frame: up to 12 months
Secondary outcomes
-
Assessment of efficacy by investigator on a 4-point scale
Time frame: after 12 months
-
Assessment of efficacy by patient on a 4-point scale
Time frame: after 12 months
-
Number of patients with adverse drug reactions
Time frame: up to 12 months
-
Assessment of tolerability by investigator on a 4-point scale
Time frame: after 12 months
-
Assessment of tolerability by patient on a 4-point scale
Time frame: after 12 months
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
Important dates
- Study start
- 1999
- Primary completion
- 2001
- First posted
- Sep 9, 2014
- Registry last updated
- Sep 9, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
NCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial DetailsGenerative AI for Medication Counselling and Adherence in Community Pharmacies
NCT07649577
Asthma, Bronchial Diseases
Amman, Jordan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
NCT06979518
Chronic Disease, Disease Attributes
Cypress, California, United States
View Trial DetailsDetecting Systemic Carbon Dioxide Levels With a Novel Biosensor
NCT06367686
Apnea, Chronic Disease
Tønsberg, Norway
View Trial Details